Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alnylam Pharmaceuticals

267.55
+0.69000.26%
Post-market: 267.550.00000.00%16:36 EDT
Volume:700.40K
Turnover:186.51M
Market Cap:34.89B
PE:-127.51
High:270.00
Open:267.27
Low:261.85
Close:266.86
Loading ...

ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals

Zacks
·
14 Jan

Piper Sandler Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)

TIPRANKS
·
13 Jan

Stifel Nicolaus Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

TIPRANKS
·
13 Jan

Alnylam Pharmaceuticals Price Target Maintained With a $320.00/Share by Needham

Dow Jones
·
13 Jan

Alnylam reports preliminary FY24 product revenues $1.646B, up 33% versus FY23

TIPRANKS
·
13 Jan

BRIEF-Alnylam Generated FY Net Product Revenues Of Over $1.6 Bln

Reuters
·
13 Jan

Alnylam Pharmaceuticals Inc - Net Product Revenues for Year of Over $1.6 Bln

THOMSON REUTERS
·
13 Jan

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals

THOMSON REUTERS
·
13 Jan

Press Release: Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals

Dow Jones
·
13 Jan

Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer -- Barrons.com

Dow Jones
·
09 Jan

Alnylam Pharmaceuticals Is Maintained at Outperform by Bernstein

Dow Jones
·
08 Jan

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Benzinga
·
04 Jan

Exploring High Growth Tech Stocks in the US December 2024

Simply Wall St.
·
27 Dec 2024

Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?

Zacks
·
25 Dec 2024

Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Performing Biotech Stock in 2024?

Insider Monkey
·
23 Dec 2024

Alnylam Pharmaceuticals: Givlaari NOW Widely Reimbursed in Canada for Treatment of Acute Hepatic Porphyria in Adults

THOMSON REUTERS
·
23 Dec 2024

The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam

Zacks
·
20 Dec 2024

4 Biotech Stocks Most Wall Street Analysts Are Bullish About

Zacks
·
20 Dec 2024

Leerink Partners Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)

TIPRANKS
·
18 Dec 2024

What Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) P/S Is Not Telling You

Simply Wall St.
·
16 Dec 2024